![]() |
市場調查報告書
商品編碼
2032920
心臟概念驗證(PoC)測試設備市場:按產品類型、最終用戶和地區分類(2026-2034 年)Cardiac PoC Testing Devices Market by Product Type (Cardiac Markers Test, Analyzers), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2026-2034 |
||||||
2025年,全球心臟概念驗證(PoC)檢測設備市場規模達21億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到32億美元,2026年至2034年的複合年成長率(CAGR)為4.72%。推動市場成長的主要因素包括:過度吸菸導致心血管疾病盛行率不斷上升;對腦鈉肽、激酶、肌鈣蛋白合成酶和乳酸脫氫酵素同功異構酵素檢測的需求日益成長;以及醫療產業的蓬勃發展。
心臟照護現場(PoC)設備是一種創新攜帶式醫療設備,旨在快速且準確地診斷心臟疾病。其體積小巧、操作簡便,並能即時提供檢測結果,使醫生能夠迅速做出恰當的患者照護決策。醫護人員可在患者床邊進行診斷測試,無需檢查室檢測,從而縮短關鍵心臟評估所需的時間。這些設備可在數分鐘內提供準確可靠的結果,並提高臨床工作流程的效率。它們還支持執行多種診斷測試,包括心臟生物標記分析、凝血監測、膽固醇譜分析和電解質測量。此外,即時檢測結果的可用性有助於更有效地進行患者分診,緩解急診室的擁塞狀況,並最佳化資源分配。隨著心臟床邊檢測設備減少對中心檢查室的依賴,最大限度地降低與檢體運輸、檢查室人員和基礎設施相關的成本,全球對這類設備的需求正在不斷成長。
目前,過度吸菸和飲酒導致心血管疾病盛行率上升是推動市場成長的關鍵因素。此外,用於檢測心肌梗塞和冠狀動脈症候群的即時心臟檢測(POC)設備在全球範圍內的使用正在增加。蓬勃發展的醫療保健產業也為市場成長提供了支持。這些設備擴大用於識別心臟衰竭期間產生的腦鈉肽、激酶、肌鈣蛋白和乳酸脫氫酵素同功異構酵素,這也對市場產生了積極影響。此外,領先企業正致力於開發基於智慧型手機的心血管疾病檢測方法。技術先進的心臟生物標記分析儀的開發也是推動市場成長的因素。此外,由於諸如提供內部標準以補償測試中固有膜變異性的軟體以及用於提高用戶便利性和可視性的內置液晶顯示螢幕等功能,對心臟分析儀的需求正在增加。最後,分析儀能夠量化全血、血清和血漿中的生物標記濃度,這對於臨床診斷非常有用,進一步促進了市場成長。此外,PoC檢測設備的科技進步日新月異,市場前景一片光明。
The global cardiac PoC testing devices market size reached USD 2.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.72% during 2026-2034. The growing prevalence of cardiovascular diseases due to excessive consumption of tobacco; rising need to detect brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes; and the thriving medical industry represent some of the key factors driving the market.
Cardiac point-of-care (PoC) testing devices are innovative and portable medical instruments designed for the rapid and accurate diagnosis of cardiac conditions. They are compact, user-friendly, and offer real-time results, enabling physicians to make prompt and informed decisions about patient care. They provide healthcare professionals with the ability to conduct diagnostic tests at the bedside of patients, eliminate the need for laboratory-based testing, and reduce turnaround times for critical cardiac assessments. They enhance the efficiency of clinical workflows by delivering accurate and reliable results within minutes. They assist in performing a variety of diagnostic tests, including cardiac biomarker analysis, coagulation monitoring, cholesterol profiling, and electrolyte measurement. They aid in obtaining immediate test results that facilitate more efficient patient triage, reduce overcrowding in emergency departments, and optimize resource allocation. As they minimize costs associated with sample transportation, lab personnel, and infrastructure by reducing the reliance on centralized laboratories, the demand for cardiac PoC testing devices is rising worldwide.
At present, the rising prevalence of cardiovascular diseases due to the excessive consumption of tobacco and alcohol represents one of the crucial factors bolstering the growth of the market. Moreover, there is an increase in the utilization of cardiac PoC testing devices to detect myocardial infarction and coronary syndromes around the world. This, along with the thriving medical industry, is supporting the growth of the market. In addition, the growing employment of these devices to identify brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes that are generated during heart failure is positively influencing the market. Besides this, key players are focusing on launching smartphone-based tests for cardiovascular diseases. They are also developing technologically advanced cardiac biomarker analyzers, which is bolstering the growth of the market. Additionally, there is a rise in the demand for cardiac analyzers, as they have software to provide an internal standard to account for membrane variability that is intrinsic to tests and integrated LCD displays for user convenience and visual clarity. This, coupled with the ability of analyzers to quantify the concentration of biomarkers in whole blood, serum, and plasma, which helps in clinical diagnosis, is impelling the growth of the market. Furthermore, the growing technological advancements in PoC testing devices are offering a favorable market outlook.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cardiac PoC testing devices. Some of the factors driving the North America cardiac PoC testing devices market included the growing cardiovascular burden among the population, increasing healthcare expenditure, rising geriatric population, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global cardiac PoC testing devices market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, ACON Laboratories Inc., Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, LifeSign LLC, Nano-Ditech Corporation, Nexus-Dx Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.